- Demonstrating impeccable timing, Achillion Pharmaceuticals (OTC:ACHN) announces that the FDA has lifted its clinical hold on sovaprevir and initial dosing has begun with ACH-3422.
- Results from the Phase 1 proof-of-concept trial for the uridine-analog nucleotide ACH-3422 are expected in the fall and combination studies should begin by year end.
- Sovaprevir testing may now begin with a once-daily maximum dose of 200 mg in HCV patients and healthy volunteers. A partial hold is still in effect for multiple dose studies in healthy volunteers which will require FDA approval of the protocol before initiating.
- Shares are up 34% premarket on higher-than-normal volume.
More good news for Achillion
Recommended For You
More Trending News
About AAQL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AAQL | - | - |
Antiaging Quantum Living Inc. |